Chemexpress(SH:688131) Zheng Quan Shi Bao Wang·2025-07-06 07:14Core Insights - Haoyuan Pharmaceutical (688131) has successfully launched its ADC CDMO base in Chongqing, achieving compliance with EU GMP standards, which positions the company to expand its domestic and international market presence [2] - The ADC sector is entering a golden development period, driven by technological advancements and clinical breakthroughs, with the global ADC market projected to exceed $100 billion by 2032 and a compound annual growth rate (CAGR) of 54.3% in China [3] - Haoyuan Pharmaceutical has established an integrated service platform from R&D to production, becoming a pioneer in the ADC field in China, with significant technological achievements and a strong pipeline of products [4] Industry Development - The ADC market is experiencing rapid growth, with the global market reaching a historical high of $3.9 billion in Q1 2025, and notable products like DS-8201 achieving over $1 billion in quarterly sales [3] - Haoyuan Pharmaceutical has built a "three-in-one" production base in Shanghai, Ma'anshan, and Chongqing, with the Chongqing facility being the largest ADC CDMO platform in Southwest China, enhancing its production capabilities [5] Technological Innovation - The company has developed a unique XDC Payload-Linker CMC integrated service platform, significantly reducing synthesis steps and production costs, exemplified by the synthesis of Erythromycin [4] - By the end of 2024, Haoyuan Pharmaceutical has completed FDA sec-DMF filings for 12 small molecule products related to ADCs, showcasing its strong technical capabilities [4] Collaborative Efforts - Haoyuan Pharmaceutical is actively forming strategic partnerships, including collaborations with AbTis Co., Ltd. for ADC innovation and with Yingbairui for process development and GMP production [7] - The company is also engaging with AI pharmaceutical firms to enhance drug discovery processes through advanced algorithms and data analysis [7] Global Expansion - Since initiating its global strategy in 2015, Haoyuan Pharmaceutical has established business centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions [8] - The company services over 95% of domestic ADC export enterprises, reflecting its platform value and customer trust in the industry [8] - Haoyuan Pharmaceutical is also exploring emerging fields such as peptide-drug conjugates (PDC) and radionuclide-drug conjugates (RDC), while leveraging AI to improve drug development efficiency [8]